Table of Contents
Thrombosis
Volume 2013, Article ID 346752, 4 pages
http://dx.doi.org/10.1155/2013/346752
Review Article

Anticoagulation for Prosthetic Valves

Department of Cardiac Surgery, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA

Received 27 July 2013; Revised 14 September 2013; Accepted 3 October 2013

Academic Editor: Giovanni de Gaetano

Copyright © 2013 Tsuyoshi Kaneko and Sary F. Aranki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. O. Bonow, B. A. Carabello, K. Chatterjee et al., “2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 52, no. 13, pp. e1–e142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. R. Massel and S. H. Little, “Antiplatelet and anticoagulation for patients with prosthetic heart valves,” Cochrane Database of Systematic Reviews, no. 7, Article ID CD003464, 2013. View at Google Scholar
  3. C. L. O'Brien and B. F. Gage, “Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation,” Journal of the American Medical Association, vol. 293, no. 6, pp. 699–706, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Heit, C. W. Colwell, C. W. Francis et al., “Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study,” Archives of Internal Medicine, vol. 161, no. 18, pp. 2215–2221, 2001. View at Google Scholar · View at Scopus
  6. B. I. Eriksson, L. Borris, O. E. Dahl et al., “Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement,” Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 121–128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. S. H. McKellar, S. Abel, C. L. Camp, R. M. Suri, M. H. Ereth, and H. V. Schaff, “Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves,” Journal of Thoracic and Cardiovascular Surgery, vol. 141, no. 6, pp. 1410–1416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. W. Eikelboom, S. J. Connolly, M. Brueckmann et al., “Dabigatran versus warfarin in patients with mechanical heart valves,” The New England Journal of Medicine, vol. 369, no. 13, pp. 1206–1214, 2013. View at Google Scholar
  9. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm250657.htm.
  10. N. H. C. Hwang, H. Reul, and P. Reinhard, “In vitro evaluation of the long-body On-X® bileaflet heart valve,” Journal of Heart Valve Disease, vol. 7, no. 5, pp. 561–568, 1998. View at Google Scholar · View at Scopus
  11. J. B. Chambers, J. L. Pomar, C. A. Mestres, and G. M. Palatianos, “Clinical event rates with the On-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years,” Journal of Thoracic and Cardiovascular Surgery, vol. 145, pp. 420–424, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. G. M. Palatianos, A. M. Laczkovics, P. Simon et al., “Multicentered European study on safety and effectiveness of the On-X prosthetic heart valve: intermediate follow-up,” Annals of Thoracic Surgery, vol. 83, no. 1, pp. 40–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. A. Williams and S. van Riet, “The On-X® heart valve: mid-term results in a poorly anticoagulated population,” Journal of Heart Valve Disease, vol. 15, no. 1, pp. 80–86, 2006. View at Google Scholar · View at Scopus
  14. J. D. Puskas, D. Nichols, M. Gerdisch et al., Reduced Anticoagulation after Mechanical Aortic Valve Replacement: Interim Results from the PROACT Randomized FDA IDE Trial, American Association of Thoracic Surgery, Minneapolis, Minn, USA, 2012.
  15. C. Mérie, L. Køber, P. S. Olsen et al., “Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding,” Journal of the American Medical Association, vol. 308, pp. 2118–2125, 2012. View at Google Scholar
  16. J. M. Castellano, R. L. Narayan, P. Vaishnava, and V. Fuster, “Anticoagulation during pregnancy in patients with a prosthetic heart valve,” Nature Reviews Cardiology, vol. 9, pp. 415–424, 2012. View at Google Scholar
  17. I. Iturbe-Alessio, M. C. Fonseca, O. Mutchinik, M. A. Santos, A. Zajarías, and E. Salazar, “Risks of anticoagulant therapy in pregnant women with artificial heart valves,” The New England Journal of Medicine, vol. 315, no. 22, pp. 1390–1393, 1986. View at Google Scholar · View at Scopus
  18. H. T. Malik, A. H. Sepehripour, A. R. Shipolini, and D. J. McCormack, “Is there a suitable method of anticoagulation in pregnant patients with mechanical prosthetic heart valves?” Interactive CardioVasc Thoracic Surgery, vol. 15, no. 3, pp. 484–488, 2012. View at Google Scholar
  19. T. G. Phan, M. Koh, and E. F. M. Wijdicks, “Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk,” Archives of Neurology, vol. 57, no. 12, pp. 1710–1713, 2000. View at Google Scholar · View at Scopus
  20. E. F. M. Wijdicks, W. I. Schievink, R. D. Brown, and C. J. Mullany, “The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves,” Neurosurgery, vol. 42, no. 4, pp. 769–773, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. The BRIDGE Study Investigators, “Bridging anticoagulation: is it needed when warfarin is interrupted around the time of a surgery or procedure?” Circulation, vol. 125, pp. e496–e498, 2012. View at Google Scholar